Literature DB >> 9184795

Multidrug resistance-associated protein: a protein distinct from P-glycoprotein involved in cytotoxic drug expulsion.

M A Barrand1, T Bagrij, S Y Neo.   

Abstract

1. Multidrug resistance (MDR) is a phenomenon originally seen in cultured tumor cells that, following selection for resistance to a single anticancer agent, become resistant to a range of chemically diverse anticancer agents. These MDR cells show a decrease in intracellular drug accumulation due to active efflux by transporter proteins. The transporter best characterized is P-glycoprotein (Pgp). This protein has been identified in many cancers and has been the target for agents able to inhibit its action, thereby reversing resistance. 2. More recently, another transporter, multidrug resistance-associated protein (MRP) has been identified in a number of MDR human tumor cell lines that do not apparently express Pgp. The presence of MRP at the cell surface of these cells is associated with alterations in drug accumulation and distribution. 3. The gene-encoding MRP has been cloned and sequenced and shown by transfection studies to be able to confer resistance and changes in drug accumulation in sensitive tumor cells. The profile of anticancer drugs expelled in the presence of MRP is similar, but not identical, to that of Pgp. 4. MRP has been identified in a number of different types of cancers, but it is not yet clear to what extent it is involved with clinical resistance. Furthermore, resistance modulators useful against Pgp are less effective in reversing MRP-mediated resistance. 5. It is not fully understood how MRP brings about drug efflux, but it is clear that the underlying mechanisms are different from those responsible for Pgp-mediated drug efflux. In particular, glutathione (GSH) is required for the effective expulsion of the anticancer agents. 6. Unlike Pgp, MRP is able to transport metallic oxyanions and glutathione and other conjugates, including peptidyl leukotrienes. Agents that inhibit organic anion transport, such as probenecid, can block MRP activity. 7. Like Pgp, MRP is expressed not only in resistant tumor cells, but also in normal human tissues. These include the epithelial cells lining the airways and the gastrointestinal tract. In cells in normal tissues, MRP appears to be located within the cytoplasm, which may mean that it functions here in a manner slightly different to that in malignant cells. It is now also recognized in cells and tissues from other species, such as the rat and mouse.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9184795     DOI: 10.1016/s0306-3623(96)00284-4

Source DB:  PubMed          Journal:  Gen Pharmacol        ISSN: 0306-3623


  15 in total

1.  Gemcitabine Cytotoxicity: Interaction of Efflux and Deamination.

Authors:  Dan Rudin; Liang Li; Nifang Niu; Krishna R Kalari; Judith A Gilbert; Matthew M Ames; Liewei Wang
Journal:  J Drug Metab Toxicol       Date:  2011-02-02

2.  Oral absorption enhancement of probucol by PEGylated G5 PAMAM dendrimer modified nanoliposomes.

Authors:  Qian Ma; Yingchun Han; Cong Chen; Yini Cao; Siling Wang; Wenwen Shen; Huayu Zhang; Yanzhi Li; Mallory A van Dongen; Bing He; Maomao Yu; Lu Xu; Mark M Banaszak Holl; George Liu; Qiang Zhang; Rong Qi
Journal:  Mol Pharm       Date:  2015-01-27       Impact factor: 4.939

3.  Inhibition of multidrug resistance-associated protein (MRP) functional activity with pluronic block copolymers.

Authors:  D W Miller; E V Batrakova; A V Kabanov
Journal:  Pharm Res       Date:  1999-03       Impact factor: 4.200

4.  Effect of organic isothiocyanates on the P-glycoprotein- and MRP1-mediated transport of daunomycin and vinblastine.

Authors:  Elaine Tseng; Amrita Kamath; Marilyn E Morris
Journal:  Pharm Res       Date:  2002-10       Impact factor: 4.200

5.  Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs.

Authors:  S Song; M G Wientjes; Y Gan; J L Au
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-18       Impact factor: 11.205

6.  Role of P glycoprotein in the course and treatment of Encephalitozoon microsporidiosis.

Authors:  G J Leitch; M Scanlon; A Shaw; G S Visvesvara
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

7.  Folic acid functionalized nanoparticles for enhanced oral drug delivery.

Authors:  Emilie Roger; Stephen Kalscheuer; Ameya Kirtane; Bharath Raja Guru; Alex E Grill; Judith Whittum-Hudson; Jayanth Panyam
Journal:  Mol Pharm       Date:  2012-06-13       Impact factor: 4.939

8.  The human multidrug-resistance-associated protein MRP1 mediates ATP-dependent transport of unconjugated bilirubin.

Authors:  Igino Rigato; Lorella Pascolo; Cristina Fernetti; J Donald Ostrow; Claudio Tiribelli
Journal:  Biochem J       Date:  2004-10-15       Impact factor: 3.857

9.  Glutathione depletion induced by c-Myc downregulation triggers apoptosis on treatment with alkylating agents.

Authors:  Annamaria Biroccio; Barbara Benassi; Francesco Fiorentino; Gabriella Zupi
Journal:  Neoplasia       Date:  2004 May-Jun       Impact factor: 5.715

10.  Influence of multidrug resistance on (18)F-FCH cellular uptake in a glioblastoma model.

Authors:  Claire Vanpouille; Nathalie Le Jeune; David Kryza; Anthony Clotagatide; Marc Janier; Francis Dubois; Nathalie Perek
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03-20       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.